13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001618205
Total reported value
$213.8M
$213.8M
69 檔
25.1%
During the Q3 2025 filing period, Birchview Capital, LP (CIK: 0001618205) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $213.8M across 69 reported positions.
Birchview Capital, LP executed strategic sector rebalancing during Q3 2025, establishing 17 new positions while fully exiting 16 holdings and trimming 19 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | KLAC | Kla CORP | Stock-Tech | 17.82% | +8.51% | +38.08% | |
| 2 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 10.79% | -2.56% | -2.02% | |
| 3 | CORT | Corcept Therapeutics Inc | Stock-Healthcare | 4.22% | +1.25% | — | |
| 4 | PRTA | Prothena Corporation plc | Stock-Other | 4.05% | -0.42% | +21.73% | |
| 5 | STOK | Stoke Therapeutics Inc | Stock-Other | 3.73% | -1.16% | — | |
| 6 | QURE | uniQure N.V. | Stock-Other | 3.47% | +0.15% | -20.23% | |
| 7 | OVV | Ovintiv Inc | Stock-Energy | 3.28% | -0.98% | — | |
| 8 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 3.04% | +0.10% | -7.27% | |
| 9 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 2.76% | -0.15% | -8.95% | |
| 10 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 2.41% | -0.09% | — | |
| 11 | CMPX | Compass Therapeutics Inc | Stock-Other | 2.31% | -2.69% | — | |
| 12 | PHR | Phreesia Inc | Stock-Other | 2.04% | -0.07% | EXIT | |
| 13 | CSTL | Castle Biosciences Inc | Stock-Other | 1.90% | -0.04% | — | |
| 14 | GPCR | Structure Therapeutics Inc | Stock-Other | 1.65% | -2.14% | +116.67% | |
| 15 | ✓ | Biodesix Inc | Stock-Other | 1.63% | +0.65% | -95.00% | |
| 16 | QDELUSD | Quidelortho CORP | Stock-Other | 1.61% | -0.04% | — | |
| 17 | AXGN | Axogen Inc | Stock-Other | 1.60% | — | -26.04% | |
| 18 | AM6 | Amicus Therapeutics Inc | Stock-Other | 1.51% | — | +803.57% | |
| 19 | HROW | Harrow Inc | Stock-Other | 1.46% | — | -33.33% | |
| 20 | EQT | Eqt CORP | Stock-Energy | 1.42% | -0.39% | — | |
| 21 | SLDB | Solid Biosciences Inc | Stock-Other | 1.38% | +0.54% | +66.11% | |
| 22 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 1.29% | -0.70% | +29.85% | |
| 23 | CYTK | Cytokinetics Inc | Stock-Healthcare | 1.24% | +0.07% | +200.00% | |
| 24 | ALKS | Alkermes plc | Stock-Healthcare | 1.13% | +0.22% | — | |
| 25 | FHTX | Foghorn Therapeutics Inc | Stock-Other | 1.04% | -0.13% | -9.39% | |
| 26 | NVCR | NovoCure Limited | Stock-Healthcare | 1.00% | -1.26% | EXIT | |
| 27 | UTHR | United Therapeutics CORP | Stock-Healthcare | 0.95% | -0.38% | -29.41% | |
| 28 | IMNM | Immunome Inc | Stock-Other | 0.93% | -0.12% | +75.00% | |
| 29 | MASI* | Masimo CORP | Stock-Other | 0.92% | — | — | |
| 30 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 0.90% | -0.60% | — | |
| 31 | TMCI | Treace Medical Concepts Inc | Stock-Other | 0.90% | — | — | |
| 32 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 0.88% | — | — | |
| 33 | OMGBP | Outset Medical Inc | Stock-Other | 0.84% | -0.22% | EXIT | |
| 34 | INBX | Inhibrx Biosciences Inc | Stock-Other | 0.81% | — | -1.28% | |
| 35 | DCGO | Docgo Inc | Stock-Other | 0.78% | — | — | |
| 36 | NTLA | Intellia Therapeutics Inc | Stock-Other | 0.78% | -0.08% | — | |
| 37 | TVTX | Travere Therapeutics Inc | Stock-Other | 0.78% | +0.28% | -58.19% | |
| 38 | PHAT | Phathom Pharmaceuticals Inc | Stock-Other | 0.76% | -0.95% | +240.00% | |
| 39 | SRRK | Scholar Rock Holding CORP | Stock-Other | 0.73% | — | +62.50% | |
| 40 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.64% | -0.11% | — | |
| 41 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 0.62% | -0.65% | EXIT | |
| 42 | HALO | Halozyme Therapeutics Inc | Stock-Healthcare | 0.56% | +0.85% | +1.00% | |
| 43 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 0.55% | +0.11% | — | |
| 44 | FCX | Freeport-mcmoran Inc | Stock-Materials | 0.53% | -0.07% | +0.06% | |
| 45 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.50% | -0.74% | EXIT | |
| 46 | PACB | Pacific Biosciences Of Calif | Stock-Other | 0.48% | -0.07% | +25.00% | |
| 47 | APGE | Apogee Therapeutics Inc | Stock-Other | 0.48% | -0.43% | EXIT | |
| 48 | ELUT | Elutia Inc | Stock-Other | 0.48% | -0.02% | -38.64% | |
| 49 | VYGR | Voyager Therapeutics Inc | Stock-Other | 0.48% | -0.04% | — | |
| 50 | ATEC | Alphatec Holdings Inc | Stock-Other | 0.36% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | QURE | uniQure N.V. | +2.7% | -20.23% | Trim |
| 2 | STOK | Stoke Therapeutics Inc | +2.5% | — | Trim |
| 3 | CMPX | Compass Therapeutics Inc | +2.3% | — | Add |
| 4 | OVV | Ovintiv Inc | +1.3% | — | Add |
| 5 | AM6 | Amicus Therapeutics Inc | +1.3% | +803.57% | Add |
| 6 | SLDB | Solid Biosciences Inc | +1% | +66.11% | Add |
| 7 | CYTK | Cytokinetics Inc | +0.9% | +200.00% | Add |
| 8 | OMGBP | Outset Medical Inc | +0.6% | +127.23% | Add |
| 9 | NVCR | NovoCure Limited | +0.5% | +1.09% | Add |
| 10 | PRTA | Prothena Corporation plc | +0.5% | +21.73% | Add |
| 11 | INBX | Inhibrx Biosciences Inc | +0.4% | -1.28% | Trim |
| 12 | PTGX | Protagonist Therapeutics Inc | +0.4% | — | Trim |
| 13 | CSTL | Castle Biosciences Inc | +0.4% | — | Add |
| 14 | KNSA | Kiniksa Pharmaceuticals International, plc | +0.3% | — | Trim |
| 15 | SRRK | Scholar Rock Holding CORP | +0.3% | +62.50% | Add |
| 16 | APGE | Apogee Therapeutics Inc | +0.2% | — | Add |
| 17 | VTYXUSD | Ventyx Biosciences Inc | +0.2% | +243.15% | Add |
| 18 | ZBIO | Zenas Biopharma Inc | +0.2% | — | Unchanged |
| 19 | NBIX | Neurocrine Biosciences Inc | +0.1% | -7.27% | Trim |
| 20 | GOSS | Gossamer Bio Inc | +0.1% | — | Unchanged |
| 21 | ATEC | Alphatec Holdings Inc | +0.1% | — | Unchanged |
| 22 | FHTX | Foghorn Therapeutics Inc | +0.1% | -9.39% | Trim |
| 23 | KPTIEUR | Karyopharm Therapeutics Inc | +0.1% | — | Unchanged |
| 24 | XENE | Xenon Pharmaceuticals Inc | 0% | — | Unchanged |
| 25 | HALO | Halozyme Therapeutics Inc | 0% | +1.00% | Add |
| 26 | TELA | Tela Bio Inc | 0% | — | Unchanged |
| 27 | IFRX | InflaRx N.V. | 0% | — | Unchanged |
| 28 | RARE | Ultragenyx Pharmaceutical In | — | +22.22% | Add |
| 29 | ZNTL | Zentalis Pharmaceuticals Inc | — | — | Unchanged |
| 30 | ALMS | Alumis Inc | 0% | — | Unchanged |
| 31 | APLSUSD | Apellis Pharmaceuticals Inc | 0% | — | Unchanged |
| 32 | CGEM | Cullinan Therapeutics Inc | 0% | — | Unchanged |
| 33 | 4XC1 | Kalvista Pharmaceuticals Inc | -0.1% | — | Trim |
| 34 | CADL | Candel Therapeutics Inc | -0.1% | — | Unchanged |
| 35 | AXSM | Axsome Therapeutics Inc | -0.1% | — | Unchanged |
| 36 | EQT | Eqt CORP | -0.2% | — | Unchanged |
| 37 | KIDS | Orthopediatrics CORP | -0.2% | -38.46% | Trim |
| 38 | HROW | Harrow Inc | -0.2% | -33.33% | Trim |
| 39 | TMCI | Treace Medical Concepts Inc | -0.3% | — | Add |
| 40 | ALKS | Alkermes plc | -0.3% | — | Unchanged |
| 41 | QDELUSD | Quidelortho CORP | -0.4% | — | Add |
| 42 | PHR | Phreesia Inc | -0.5% | — | Unchanged |
| 43 | MASI* | Masimo CORP | -0.7% | — | Trim |
| 44 | AXGN | Axogen Inc | -1% | -26.04% | Trim |
| 45 | ACAD | Acadia Pharmaceuticals Inc | -1% | -8.95% | Trim |
| 46 | UTHR | United Therapeutics CORP | -1.1% | -29.41% | Trim |
| 47 | DCGO | Docgo Inc | -1.2% | — | Trim |
| 48 | TVTX | Travere Therapeutics Inc | -1.4% | -58.19% | Trim |
| 49 | ✓ | Biodesix Inc | -1.5% | -95.00% | Trim |
| 50 | ELUT | Elutia Inc | -2.1% | -38.64% | Trim |
According to official SEC Form 13F filings, Birchview Capital, LP reported a total U.S. public equity portfolio value of $213.8M across 69 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including KLAC, BMY, CORT) accounted for 25.1% of total reported equity market value during Q3 2025.
Top New Position Initiated
KLAC
市值: $23.6M
Top Position Liquidated / Trimmed
TXG
前期市值: $436.5K
During Q3 2025, Birchview Capital, LP's top holdings by market value included KLAC (17.8%)、BMY (10.8%)、CORT (4.2%). The largest single position, KLAC, represented 17.8% of total portfolio value.
In Q3 2025, Birchview Capital, LP made 69 total portfolio adjustments, initiating 17 new buys, adding to 17 positions, trimming 19 holdings, and fully liquidating 16 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.